世界の眼科用薬市場2022-2030:薬剤分類別、疾患別(ドライアイ、緑内障)、剤形別、投与経路別、製品タイプ別(処方薬、OTC薬)、地域別

【英語タイトル】Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease (Dry Eye, Glaucoma), By Dosage Form, By Route of Administration, By Product Type (Prescription, OTC), By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV064)・商品コード:GRV22NV064
・発行会社(調査会社):Grand View Research
・発行日:2022年10月21日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界の眼科用薬市場規模が、2022年から2030年の間に年平均7.7%成長し、2030年までに656億ドルに達すると予測しています。当調査レポートでは、眼科用薬の世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、産業見通し、薬剤分類別(抗アレルギー薬、抗VEGF薬、抗炎症薬、抗緑内障薬、その他)分析、疾患別(ドドライアイ、アレルギー、緑内障、眼感染症、その他)分析、剤形別(ゲル、溶液&懸濁液、カプセル&錠剤、目薬、軟膏)分析、製品タイプ別(処方薬、OTC薬)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争分析などの構成でまとめています。なお、当書に掲載されている企業情報には、ALCON、NOVARTIS AG、JOHNSON & JOHNSON SERVICES, INC.、BAUSCH HEALTH、MERCK & CO. INC.、REGENERON PHARMACEUTICALS, INC.、COHERUS BIOSCIENCES, INC.、ALLERGAN、PFIZER, INC.、BAYER AG、SANTEN PHARMACEUTICALS CO. LTD.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業見通し
・世界の眼科用薬市場規模:薬剤分類別
- 抗アレルギー薬の市場規模
- 抗VEGF薬の市場規模
- 抗炎症薬の市場規模
- 抗緑内障薬の市場規模
- その他眼科用薬の市場規模
・世界の眼科用薬市場規模:疾患別
- ドライアイにおける市場規模
- アレルギーにおける市場規模
- 緑内障における市場規模
- 眼感染症における市場規模
- その他疾患における市場規模
・世界の眼科用薬市場規模:剤形別
- ゲルの市場規模
- 溶液&懸濁液の市場規模
- カプセル&錠剤の市場規模
- 目薬の市場規模
- 軟膏の市場規模
・世界の眼科用薬市場規模:製品タイプ別
- 処方薬の市場規模
- OTC薬の市場規模
・世界の眼科用薬市場規模:地域別
- 北米の眼科用薬市場規模
- ヨーロッパの眼科用薬市場規模
- アジア太平洋の眼科用薬市場規模
- 中南米の眼科用薬市場規模
- 中東・アフリカの眼科用薬市場規模
・競争分析

Ophthalmic Drugs Market Growth & Trends

The global ophthalmic drugs market size is expected to reach USD 65.6 billion by 2030, garnering a CAGR of 7.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights

• Anti-VEGF agents segment held the largest share in 2021 owing to their rising demand and lesser adverse effects

• Retinal disorders held the largest market share in 2021 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy

• The topical route of administration dominated the market in 2021 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use

• The eye drops segment is expected to hold the largest share in 2021 owing to rising demand for eye drops, high patient compliance, and availability of OTC products

• Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Ophthalmic Drugs Market: Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 3: Country Wise Market Estimation Using Top Down Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Ophthalmic Drugs Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Ophthalmic Drugs Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.2 Regulatory Framework
3.2.1 Regulatory Bodies, By Region
3.2.2 North America
3.2.3 Europe
3.2.4 Asia Pacific
3.2.5 Latin America
3.2.6 Middle East & Africa
3.3 Patent Expiry Analysis
3.4 Pipeline Analysis
3.4.1 Pipeline Analysis, By Phase (Funder Type- Industry)
3.4.2 Pipeline Analysis, By Phase (Funder Type- All Others)
3.5 Cost Structure Analysis
3.6 Market Dynamics
3.6.1 Market Drivers Analysis
3.6.1.1 Increasing Disease Prevalence
3.6.1.2 Strong Developmental Pipeline
3.6.1.3 Advancements In Drug Delivery
3.6.1.4 Promising Investment Scenario
3.6.2 Market Restraint Analysis
3.6.2.1 Patent Expiry Of Blockbuster Drugs
3.7 Penetration & Growth Prospect Mapping
3.8 Ophthalmic Drugs: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 Pestle Analysis
3.8.3 Major Deals And Strategic Alliances
3.8.3.1 New Product Launch
3.8.3.2 Acquisition
3.8.3.3 Expansion
3.8.3.4 Partnerships
3.8.3.5 Marketing & Promotions
3.9 Primary Research Analysis
3.9.1 Market Scenario
3.9.2 Key Kol Responses
Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2018 – 2030 (USD Million)
4.1 Definition and Scope
4.2 Drug Class Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Ophthalmic Drugs Market, by Drug Class, 2018 – 2030 (USD Million)
4.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
4.5.1 Antiallergy
4.5.1.1 Antiallergy Market, 2018 – 2030 (USD Million)
4.5.2 Anti-Vegf Agents
4.5.2.1 Anti-Vegf Agents Market, 2018 – 2030 (USD Million)
4.5.3 Anti-Inflammatory
4.5.3.1 Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.3.2 Non-Steroidal Anti-Inflammatory Drugs
4.5.3.2.1 Non-Steroidal Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.3.3 Steroidal Anti-Inflammatory Drugs
4.5.3.3.1 Steroidal Anti-Inflammatory Market, 2018 – 2030 (USD Million)
4.5.4 Antiglaucoma
4.5.4.1 Antiglaucoma Market, 2018 – 2030 (USD Million)
4.5.5 Others
4.5.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2018 – 2030 (USD Million)
5.1 Definition and Scope
5.2 Disease Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Ophthalmic Drugs Market, by Disease, 2018 – 2030 (USD Million)
5.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
5.5.1 Dry Eye
5.5.1.1 Dry Eye Market, 2018 – 2030 (USD Million)
5.5.2 Eye Allergies
5.5.2.1 Eye Allergies Market, 2018 – 2030 (USD Million)
5.5.3 Glaucoma
5.5.3.1 Glaucoma Market, 2018 – 2030 (USD Million)
5.5.4 Eye Infection
5.5.4.1 Eye Infection Market, 2018 – 2030 (USD Million)
5.5.5 Retinal Disorders
5.5.5.1 Retinal Disorders Market, 2018 – 2030 (USD Million)
5.5.5.2 Macular Degeneration
5.5.5.2.1 Macular Degeneration Market, 2018 – 2030 (USD Million)
5.5.5.3 Diabetic Retinopathy
5.5.5.3.1 Diabetic Retinopathy Market, 2018 – 2030 (USD Million)
5.5.5.4 Others
5.5.5.4.1 Others Market, 2018 – 2030 (USD Million)
5.5.6 Uveitis
5.5.6.1 Uveitis Market, 2018 – 2030 (USD Million)
5.5.7 Others
5.5.7.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2018 – 2030 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2018 – 2030 (USD Million)
6.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
6.5.1 Topical
6.5.1.1 Topical Market, 2018 – 2030 (USD Million)
6.5.2 Local Ocular
6.5.2.1 Local Ocular Market, 2018 – 2030 (USD Million)
6.5.2.2 Subconjunctival
6.5.2.2.1 Subconjunctival Market, 2018 – 2030 (USD Million)
6.5.2.3 Intravitreal
6.5.2.3.1 Intravitreal Market, 2018 – 2030 (USD Million)
6.5.2.4 Retrobulbar
6.5.2.4.1 Retrobulbar Market, 2018 – 2030 (USD Million)
6.5.2.5 Intracameral
6.5.2.5.1 Intracameral Market, 2018 – 2030 (USD Million)
6.5.3 Systemic
6.5.3.1 Systemic Market, 2018 – 2030 (USD Million)
Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2018 – 2030 (USD Million)
7.1 Definition and Scope
7.2 Dosage Form Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2018 – 2030 (USD Million)
7.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
7.5.1 Gels
7.5.1.1 Gels Market, 2018 – 2030 (USD Million)
7.5.2 Eye Solutions And Suspensions
7.5.2.1 Eye Solutions And Suspensions Market, 2018 – 2030 (USD Million)
7.5.3 Capsules & Tablets
7.5.3.1 Capsules & Tablets Market, 2018 – 2030 (USD Million)
7.5.4 Eye Drops
7.5.4.1 Eye Drops Market, 2018 – 2030 (USD Million)
7.5.5 Ointments
7.5.5.1 Ointments Market, 2018 – 2030 (USD Million)
Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2018 – 2030 (USD Million)
8.1 Definition and Scope
8.2 Product Type Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Ophthalmic Drugs Market, by Product Type, 2018 – 2030 (USD Million)
8.5 Market Size & Forecasts and Trend Analyses, 2018 – 2030 (USD Million)
8.5.1 Otc Drugs
8.5.1.1 Otc Drugs Market, 2018 – 2030 (USD Million)
8.5.2 Prescription Drugs
8.5.2.1 Prescription Drugs Market, 2018 – 2030 (USD Million)
Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2021 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Regional Market Share and Leading Players, 2021
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East & Africa
9.6 Swot Analysis
9.6.1 North America
9.6.2 Europe
9.6.3 Asia Pacific
9.6.4 Latin America
9.6.5 Middle East & Africa
9.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 – 2030 (USD Million)
9.7.1 North America
9.7.1.1 North America Ophthalmic Drugs Market, 2018-2030 (USD Million)
9.7.1.2 U.S.
9.7.1.2.1 U.S. Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.1.3 Canada
9.7.1.3.1 Canada Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2 Europe
9.7.2.1 Europe Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.2 UK
9.7.2.2.1 UK Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.3 Germany
9.7.2.3.1 Germany Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.4 France
9.7.2.4.1 France Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.5 Italy
9.7.2.5.1 Italy Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.6 Spain
9.7.2.6.1 Spain Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.2.7 Russia
9.7.2.7.1 Russia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3 Asia PacificC
9.7.3.1 Asia Pacific Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.2 Japan
9.7.3.2.1 Japan Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.3 China
9.7.3.3.1 China Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.4 India
9.7.3.4.1 India Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.5 Australia
9.7.3.5.1 Australia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.6 South Korea
9.7.3.6.1 South Korea Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.3.7 Singapore
9.7.3.7.1 Singapore Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4 Latin America
9.7.4.1 Latin America Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.2 Mexico
9.7.4.2.1 Mexico Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.3 Brazil
9.7.4.3.1 Brazil Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.4.4 Argentina
9.7.4.4.1 Argentina Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5 Middle East & Africa
9.7.5.1 Middle East & Africa Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.2 South Africa
9.7.5.2.1 South Africa Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.3 UAE
9.7.5.3.1 UAE Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
9.7.5.4 Saudi Arabia
9.7.5.4.1 Saudi Arabia Ophthalmic Drugs Market, 2018 – 2030 (USD Million)
Chapter 10 Ophthalmic Drugs Market: Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff Matrix
10.1.2 Heat Map Analysis
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List Of Key Distributors And Channel Partners
10.3.2 Key Customers
10.3.3 Key Company Market Share Analysis, 2021
10.4 Public Companies
10.4.1 Company Market Position Analysis
10.4.2 Company Market Share, By Region
10.4.3 Competitive Dashboard Analysis
10.4.3.1 Market Differentiators
10.5 Private Companies
10.5.1 List Of Key Emerging Companies
10.5.2 Regional Network Map
10.5.3 Company Market Position Analysis
10.6 Company Profiles
10.6.1 ALCON
10.6.1.1 Company Overview
10.6.1.2 Financial Performance
10.6.1.3 Product Benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 NOVARTIS AG
10.6.2.1 Company Overview
10.6.2.2 Financial Performance
10.6.2.3 Product Benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 JOHNSON & JOHNSON SERVICES, INC.
10.6.3.1 Company Overview
10.6.3.2 Financial Performance
10.6.3.3 Product Benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 BAUSCH HEALTH
10.6.4.1 Company Overview
10.6.4.2 Financial Performance
10.6.4.3 Product Benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 MERCK & CO. INC.
10.6.5.1 Company Overview
10.6.5.2 Financial Performance
10.6.5.3 Product Benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 REGENERON PHARMACEUTICALS, INC.
10.6.6.1 Company Overview
10.6.6.2 Financial Performance
10.6.6.3 Product Benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 COHERUS BIOSCIENCES, INC.
10.6.7.1 Company Overview
10.6.7.2 Financial Performance
10.6.7.3 Product Benchmarking
10.6.7.4 Strategic Initiatives
10.6.8 ALLERGAN
10.6.8.1 Company Overview
10.6.8.2 Financial Performance
10.6.8.3 Product Benchmarking
10.6.8.4 Strategic Initiatives
10.6.9 PFIZER, INC.
10.6.9.1 Company Overview
10.6.9.2 Financial Performance
10.6.9.3 Product Benchmarking
10.6.9.4 Strategic Initiatives
10.6.10 BAYER AG
10.6.10.1 Company Overview
10.6.10.2 Financial Performance
10.6.10.3 Product Benchmarking
10.6.10.4 Strategic Initiatives
10.6.11 SANTEN PHARMACEUTICALS CO. LTD.
10.6.11.1 Company Overview
10.6.11.2 Financial Performance
10.6.11.3 Product Benchmarking
10.6.11.4 Strategic Initiatives
10.6.12 GENETECH, INC.
10.6.12.1 Company Overview
10.6.12.2 Financial Performance
10.6.12.3 Product Benchmarking
10.6.12.4 Strategic Initiatives



★調査レポート[世界の眼科用薬市場2022-2030:薬剤分類別、疾患別(ドライアイ、緑内障)、剤形別、投与経路別、製品タイプ別(処方薬、OTC薬)、地域別] (コード:GRV22NV064)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の眼科用薬市場2022-2030:薬剤分類別、疾患別(ドライアイ、緑内障)、剤形別、投与経路別、製品タイプ別(処方薬、OTC薬)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆